HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study.

Abstract
Infusional, cyclic PGE1 treatment is effective in patients with intermittent claudication and critical limb ischemia (CLI). One of the problems related to chronic PGE1 treatment in vascular diseases due to atherosclerosis is to evaluate the variations of clinical conditions due to treatment in order to establish the number of cycles per year or per period (in severe vascular disease reevaluation of patients should be more frequent) needed to achieve clinical improvement. In a preliminary pilot study a group of 150 patients (mean age 67+/-12 years) with intermittent claudication (walking range from 0 to 500 m) and a group of 100 patients with CLI (45% with rest pain, and 55% gangrene; mean age 68 +/-11 years) the number of PGE1 cycles according to the short-term protocol (STP) needed to produce significant clinical improvement was preliminarily evaluated. Considering these preliminary observations, the investigators established a research plan useful to produce nomograms indicating the number of cycles of PGE1-STP per year needed to improve the clinical condition (both in intermittent claudication and CLI). A significant clinical improvement was arbitrarily defined as the increase of at least 35% in walking distance (on treadmill) and/or the disappearance of signs and symptoms of critical ischemia in 6 months of treatment in at least 75% of the treated patients. With consideration of the results obtained with the preliminary nomograms a larger validation of the nomograms is now advisable. A cost-effectiveness analysis is also useful to define the efficacy of treatment on the basis of its costs. The publication of this report in two angiological journals (Angeiologie and Angiology) will open the research on nomograms to all centers willing to collaborate to the study. The data are being collected in the ORACL.E database and will be analyzed within 12 months after the publication of this report.
AuthorsG Belcaro, A N Nicolaides, G Cipollone, G Laurora, L Incandela, M Cazaubon, A Barsotti, A Ledda, B M Errichi, U Cornelli, M Dugall, M Corsi, L Mezzanotte, G Geroulakos, C Fisher, G Szendro, E Simeone, M R Cesarone, M Bucci, G Agus, M T De Sanctis, A Ricci, E Ippolito, S Vasdekis, D Christopoulos, H Helmis
JournalAngiology (Angiology) Vol. 51 Issue 8 Pt 2 Pg. S3-13; discussion S14 (Aug 2000) ISSN: 0003-3197 [Print] United States
PMID10959506 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Vasodilator Agents
  • Alprostadil
Topics
  • Aged
  • Algorithms
  • Alprostadil (administration & dosage, economics)
  • Cost-Benefit Analysis
  • Drug Costs
  • Female
  • Humans
  • Intermittent Claudication (drug therapy, etiology)
  • Ischemia (complications, drug therapy)
  • Leg (blood supply)
  • Male
  • Middle Aged
  • Pain (drug therapy, etiology)
  • Pilot Projects
  • Treatment Outcome
  • Vasodilator Agents (administration & dosage, economics)
  • Walking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: